These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 25096664)

  • 1. Long-term macrolide therapy in chronic obstructive pulmonary disease.
    Parameswaran GI; Sethi S
    CMAJ; 2014 Oct; 186(15):1148-52. PubMed ID: 25096664
    [No Abstract]   [Full Text] [Related]  

  • 2. The cardiovascular safety of azithromycin.
    Juurlink DN
    CMAJ; 2014 Oct; 186(15):1127-8. PubMed ID: 25096666
    [No Abstract]   [Full Text] [Related]  

  • 3. Influence of macrolide maintenance therapy and bacterial colonisation on exacerbation frequency and progression of COPD (COLUMBUS): study protocol for a randomised controlled trial.
    Uzun S; Djamin RS; Kluytmans J; Van't Veer NE; Ermens AA; Pelle AJ; Mulder P; van der Eerden MM; Aerts J
    Trials; 2012 Jun; 13():82. PubMed ID: 22682323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of long-term macrolide therapy in chronic obstructive pulmonary disease.
    Ramos FL; Criner GJ
    Curr Opin Pulm Med; 2014 Mar; 20(2):153-8. PubMed ID: 24378875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacotherapy for lower respiratory tract infections.
    Liapikou A; Torres A
    Expert Opin Pharmacother; 2014 Nov; 15(16):2307-18. PubMed ID: 25216725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [COPD and bacterial colonization: therapeutic implications].
    Gómez J; Baños V; García Martín E
    Rev Esp Quimioter; 2005 Jun; 18(2):187-91. PubMed ID: 16130042
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of long-term macrolide therapy at low doses in stable COPD.
    Cao Y; Xuan S; Wu Y; Yao X
    Int J Chron Obstruct Pulmon Dis; 2019; 14():1289-1298. PubMed ID: 31354258
    [No Abstract]   [Full Text] [Related]  

  • 8. [Antimicrobial therapy in exacerbated chronic obstructive pulmonary disease].
    Alvarez F; Bouza E; García-Rodríguez JA; Mayer MA; Mensa J; Monsó E; Nodar E; Picazo JJ; Sobradillo V; Torres A;
    Arch Bronconeumol; 2002 Feb; 38(2):81-9. PubMed ID: 11844440
    [No Abstract]   [Full Text] [Related]  

  • 9. Rising to the challenge of resistance: a case study-based discussion.
    Housset B
    Int J Antimicrob Agents; 2007 Feb; 29 Suppl 1():S11-6. PubMed ID: 17307651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycoplasma pneumoniae in children: carriage, pathogenesis, and antibiotic resistance.
    Meyer Sauteur PM; van Rossum AM; Vink C
    Curr Opin Infect Dis; 2014 Jun; 27(3):220-7. PubMed ID: 24751894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risks of population antimicrobial resistance associated with chronic macrolide use for inflammatory airway diseases.
    Serisier DJ
    Lancet Respir Med; 2013 May; 1(3):262-74. PubMed ID: 24429132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term macrolide treatment for chronic respiratory disease.
    Spagnolo P; Fabbri LM; Bush A
    Eur Respir J; 2013 Jul; 42(1):239-51. PubMed ID: 23180583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and abundance of selected genes conferring macrolide resistance genes in COPD patients during maintenance treatment with azithromycin.
    Djamin RS; Talman S; Schrauwen EJA; von Wintersdorff CJH; Wolffs PF; Savelkoul PHM; Uzun S; Kerstens R; van der Eerden MM; Kluytmans JAJW
    Antimicrob Resist Infect Control; 2020 Jul; 9(1):116. PubMed ID: 32723393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implications of macrolide resistance in community-acquired respiratory tract infections.
    Hoban DJ; Zhanel GG
    Expert Rev Anti Infect Ther; 2006 Dec; 4(6):973-80. PubMed ID: 17181414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pseudomonas aeruginosa infections in chronic obstructive pulmonary disease : Role of long-term antibiotic treatment].
    Rohde GGU; Welte T
    Internist (Berl); 2017 Nov; 58(11):1142-1149. PubMed ID: 28983645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hidden epidemic of macrolide-resistant pneumococci.
    Klugman KP; Lonks JR
    Emerg Infect Dis; 2005 Jun; 11(6):802-7. PubMed ID: 15963272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Chronic Respiratory Pasteurella multocida Infection Is Well-Controlled by Long-Term Macrolide Therapy.
    Seki M; Sakata T; Toyokawa M; Nishi I; Tomono K
    Intern Med; 2016; 55(3):307-10. PubMed ID: 26831030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BTS guideline for the use of long-term macrolides.
    Congleton J
    Drug Ther Bull; 2021 May; 59(5):67-68. PubMed ID: 33753351
    [No Abstract]   [Full Text] [Related]  

  • 19. [Acute exacerbations due to Streptococcus pneumoniae in chronic lower respiratory tract infections during long-term macrolide therapy].
    Maeda K; Mikasa K; Konishi M; Takahashi K; Majima T; Murakawa K; Yoshimoto E; Sakamoto M; Narita N; Sano R; Masutani T; Nakamura S
    Kansenshogaku Zasshi; 2001 Oct; 75(10):846-50. PubMed ID: 11712358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Community-acquired pneumococcal infection: approach to improve the election of antibiotic therapy].
    Oteo J; Alós JI
    Med Clin (Barc); 2003 Mar; 120(8):297-302. PubMed ID: 12636900
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.